ReviewFrontiers in medicine2026
Management of diabetic macular edema: from anti-VEGF to emerging therapies.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic macular edema (DME) is a frequent and vision-threatening complication of diabetes, arising from a complex interplay of inflammatory, vascular, and metabolic pathways. The advent of anti-vascular endothelial growth factor (anti-VEGF) therapy has fundamentally transformed DME management and is now established as the cornerstone of treatment. In this review, we provide an updated overview of current and emerging therapeutic approaches for DME. We summarize the clinical evidence supporting established anti-VEGF agents, including ranibizumab, aflibercept, and conbercept, as well as the complementary roles of intravitreal corticosteroids and subthreshold micropulse laser therapy. Particular emphasis is placed on recent advances, such as dual-pathway inhibition with faricimab, the potential retinal benefits of systemic agents including sodium-glucose cotransporter-2 inhibitors and metformin, and novel strategies aimed at improving treatment durability, including long-acting anti-VEGF formulations and gene-based therapies. Together, these developments reflect a shift toward more sustained, individualized, and mechanism-based management of DME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.